PremiumThe FlyTeva holds a pharmaceutical update conference call Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study Teva, Alvotech announces U.S. availability of SELARSDI injection PremiumMarket NewsShares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute Axsome announces settlement agreement resolving AUVELITY patent litigation Teva files automatic mixed securities shelf PremiumThe FlyTeva price target lowered to $26 from $28 at Barclays Teva Pharmaceuticals Reports Continued Growth in 2024 Teva price target lowered to $23 from $26 at BofA 
